A Phase 1 interventional study of TAK-881 and HyQvia in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults.
Study participants will receive a single dose of TAK-881 or HyQvia on Day 1.
During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive TAK-881, 1.0 gram per Kilogram (g/kg), single subcutaneous (SC) injection using investigational needle sets on Day 1.
Biological: TAK-881 · Device: SC Investigational Needle Sets
Participants will receive HyQvia, 1.0 g/kg, single SC injection using investigational needle sets on Day 1.
Biological: HyQvia · Device: SC Investigational Needle Sets
Participants will receive SC infusion of TAK-881.
Also known as: Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)
Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase
Participants will receive SC infusion of HyQvia.
Also known as: Immune Globulin Subcutaneous (Human), 10% Solution with rHuPH20
The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
The single-use only SC needle set will be used to administer HyQvia to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
Baseline-corrected Area Under the Concentration-time Curve (AUC) From Day 1 to Day 29 (AUC Day 1-29) Based on Serum Total Immunoglobulin G (IgG) Levels
Baseline-corrected AUC Day 1-29 based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
Time frame: Day 1 up to Day 29
Baseline-uncorrected Maximum Observed Concentration (Cmax) Based on Serum Total IgG Levels
Baseline-uncorrected Cmax based on serum total IgG levels was reported for TAK-881 and HyQvia.
Time frame: Day 1 up to Day 85
Baseline-uncorrected Time to Maximum Concentration (Tmax) Based on Serum Total IgG Levels
Baseline-uncorrected Tmax based on serum total IgG levels was reported for TAK-881 and HyQvia.
Time frame: Day 1 up to Day 85
Baseline-uncorrected AUC Day1-29 Based on Serum Total IgG Levels
Baseline-uncorrected AUC Day1-29 based on serum total IgG levels was reported for TAK-881 and HyQvia.
Time frame: Day 1 up to Day 29
Baseline-corrected AUC From Day 1 to Infinity (AUCinf) Based on Serum Total IgG Levels
Baseline-corrected AUCinf based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
Time frame: Day 1 up to Day 85
Baseline-corrected AUC From Day 1 to Time of the Last Measurable Concentration (AUClast) Based on Serum Total IgG Levels
Baseline-corrected AUClast based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
Time frame: Day 1 up to Day 85
Baseline-corrected Cmax Based on Serum Total IgG Levels
Baseline-corrected Cmax based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
Time frame: Day 1 up to Day 85
Baseline-corrected Tmax Based on Serum Total IgG Levels
Baseline-corrected Tmax based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
Time frame: Day 1 up to Day 85
Baseline-corrected Time of Last Measurable Concentration (Tlast) Based on Serum Total IgG Levels
Baseline-corrected Tlast based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
Time frame: From Day 1 up to Day 85
Baseline-corrected Terminal Half-life (t1/2z) Based on Serum Total IgG Levels
Baseline-corrected t1/2z based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
Time frame: Day 1 up to Day 85
Baseline-corrected Apparent Clearance (CL/F) Based on Serum Total IgG Levels
Baseline-corrected CL/F based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
Time frame: Day 1 up to Day 85
Baseline-corrected Apparent Volume of Distribution (Vz/F) Based on Serum Total IgG Levels
Baseline-corrected Vz/F based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
Time frame: Day 1 up to Day 85
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An Adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any AE that was starting or worsening at the time of or after dosing of investigational product (IP).
Time frame: From start of study drug up to end of trial (up to Day 85)
Number of Participants With Infusion Withdrawals, Interruptions, and Infusion Rate Reductions
The number of participants with infusion withdrawals, interruptions, and infusion rate reductions due to TAK-881 or HyQvia related TEAEs were reported.
Time frame: On Day 1 (day of the first and only infusion)
Number of Participants With Positive Binding Antibodies to rHuPH20
Number of participants with positive binding antibodies to recombinant human hyaluronidase (rHuPH20) with titer greater than or equal to (\>=) 1:160 were reported.
Time frame: At Days -1, 29, and 85
Number of Participants With Neutralizing Antibodies to rHuPH20
Number of participants with neutralizing antibodies to rHuPH20 were reported.
Time frame: At Days -1, 29, and 85
This study was conducted at single center in the United States from 24 March 2025 to 8 August 2025.
| Milestone | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Started | 15 | 15 |
| Pharmacokinetic per-protocol analysis set (pkppas) | 13 | 15 |
| Completed | 13 | 14 |
| Not completed | 2 | 1 |
| Withdrew: Failed drug/alcohol laboratory | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Baseline-corrected AUC Day 1-29 based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
| gram*hour per liter (g*h/L) | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-corrected Area Under the Concentration-time Curve (AUC) From Day 1 to Day 29 (AUC Day 1-29) Based on Serum Total Immunoglobulin G (IgG) Levels | 2993 ± 13.6 | 3190 ± 25.4 |
Baseline-uncorrected Cmax based on serum total IgG levels was reported for TAK-881 and HyQvia.
| gram per liter (g/L) | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-uncorrected Maximum Observed Concentration (Cmax) Based on Serum Total IgG Levels | 19.84 ± 15.9 | 20.70 ± 13.0 |
Baseline-uncorrected Tmax based on serum total IgG levels was reported for TAK-881 and HyQvia.
| hours | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-uncorrected Time to Maximum Concentration (Tmax) Based on Serum Total IgG Levels | 167.741 (119.75 to 167.86) | 143.829 (118.94 to 671.80) |
Baseline-uncorrected AUC Day1-29 based on serum total IgG levels was reported for TAK-881 and HyQvia.
| g*h/L | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-uncorrected AUC Day1-29 Based on Serum Total IgG Levels | 10310 ± 13.8 | 10720 ± 10.5 |
Baseline-corrected AUCinf based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
| g*h/L | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-corrected AUC From Day 1 to Infinity (AUCinf) Based on Serum Total IgG Levels | 4556 ± 18.4 | 5425 ± 41.4 |
Baseline-corrected AUClast based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
| g*h/L | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-corrected AUC From Day 1 to Time of the Last Measurable Concentration (AUClast) Based on Serum Total IgG Levels | 4240 ± 21.0 | 4591 ± 43.2 |
Baseline-corrected Cmax based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
| g/L | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-corrected Cmax Based on Serum Total IgG Levels | 8.875 ± 21.2 | 9.486 ± 21.8 |
Baseline-corrected Tmax based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
| hours | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-corrected Tmax Based on Serum Total IgG Levels | 167.741 (119.75 to 167.86) | 143.829 (118.94 to 671.80) |
Baseline-corrected Tlast based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
| hours | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-corrected Time of Last Measurable Concentration (Tlast) Based on Serum Total IgG Levels | 2015.748 (575.93 to 2015.84) | 2015.705 (504.11 to 2016.97) |
Baseline-corrected t1/2z based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
| hours | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-corrected Terminal Half-life (t1/2z) Based on Serum Total IgG Levels | 146.613 (42.28 to 454.04) | 165.913 (37.83 to 951.45) |
Baseline-corrected CL/F based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
| liter per hour (L/h) | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-corrected Apparent Clearance (CL/F) Based on Serum Total IgG Levels | 0.01579 ± 0.0029847 | 0.01429 ± 0.0050489 |
Baseline-corrected Vz/F based on serum total IgG levels was reported for TAK-881 and HyQvia. Baseline-corrected concentration is equal to serum total IgG post-dose concentration minus the baseline concentration.
| Liters (L) | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Baseline-corrected Apparent Volume of Distribution (Vz/F) Based on Serum Total IgG Levels | 4.169 ± 2.7106 | 3.823 ± 2.7628 |
An Adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was defined as any AE that was starting or worsening at the time of or after dosing of investigational product (IP).
| Participants | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 15 | 15 |
The number of participants with infusion withdrawals, interruptions, and infusion rate reductions due to TAK-881 or HyQvia related TEAEs were reported.
| Participants | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Number of Participants With Infusion Withdrawals, Interruptions, and Infusion Rate Reductions | 0 | 0 |
Number of participants with positive binding antibodies to recombinant human hyaluronidase (rHuPH20) with titer greater than or equal to (\>=) 1:160 were reported.
| Participants | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| At Day -1 | 0 | 0 |
| At Day 29 | 0 | 0 |
| At Day 85 | 0 | 0 |
Number of participants with neutralizing antibodies to rHuPH20 were reported.
| Participants | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| At Day -1 | 0 | 0 |
| At Day 29 | 0 | 0 |
| At Day 85 | 0 | 0 |
Collected over From start of study drug up to end of trial (up to Day 85). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAK-881 1.0 g/kg | 0/15 (0%) | 0/15 (0%) | 15/15 (100%) |
| HyQvia 1.0 g/kg | 0/15 (0%) | 0/15 (0%) | 15/15 (100%) |
| Event | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg |
|---|---|---|
| Infusion site erythemaGeneral disorders | 14/15 | 15/15 |
| Infusion site swellingGeneral disorders | 15/15 | 14/15 |
| Infusion site pruritusGeneral disorders | 8/15 | 11/15 |
| HeadacheNervous system disorders | 9/15 | 9/15 |
| Infusion site painGeneral disorders | 8/15 | 9/15 |
| Feeling hotGeneral disorders | 4/15 | 5/15 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/15 | 4/15 |
| Infusion site discomfortGeneral disorders | 1/15 | 4/15 |
| ChillsGeneral disorders | 3/15 | 2/15 |
| NauseaGastrointestinal disorders | 2/15 | 3/15 |
Safety analysis set included all participants who received any amount of TAK-881 or HyQvia.
| Age, Continuous(years) | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg | Total |
|---|---|---|---|
| Mean | 34.9 ± 9.14 | 38.3 ± 6.98 | 36.6 ± 8.18 |
| Sex: Female, Male(Participants) | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg | Total |
|---|---|---|---|
| Female | 12 | 10 | 22 |
| Male | 3 | 5 | 8 |
| Ethnicity (NIH/OMB)(Participants) | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 15 | 29 |
| Not Hispanic or Latino | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | TAK-881 1.0 g/kg | HyQvia 1.0 g/kg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 3 |
| White | 11 | 15 | 26 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2025 to primary completion in Jul 2025, 4 months.
Results were first posted in May 2026, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Immunoglobulins, Intravenous · Immunoglobulin G · Hyaluronoglucosaminidase